MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Veliparib dihydrochloride

CAS No. : 912445-05-7

MCE 站：Veliparib dihydrochloride

产品活性：Veliparib dihydrochloride是有效的 PARP1 和 PARP2 抑制剂，K_i 分别为5.2 nM，2.9 nM。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics  |  Autophagy

作用靶点：PARP  |  Autophagy

In Vitro: Veliparib is inactive to SIRT2 (>5 μM).?Veliparib inhibits the PARP activity with EC₅₀ of 2 nM in C41 cells. Veliparib can decrease the PAR levels in both irradiated and nonirradiated H460 cells. Veliparib reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. Veliparib increases apoptosis and autophagy in H460 cells when combination with radiation.?Veliparib inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. Veliparib (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. Veliparib shows effective radiosensitivity in oxic H1299 cells. Veliparib can attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1.

In Vivo: The oral bioavailability of Veliparib is 56%-92% in mice, SD rats, beagle dogs, and cynomolgus monkeys after oral administration.?Veliparib (25 mg/kg, i.p.) can improve tumor growth delay in a NCI-H460 xenograft model. Combination with radiation, veliparib decreases the tumor vessel formation.?Veliparib reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression can be maintained over time.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  XAV-939  |  Rucaparib  |  PJ34  |  3-Aminobenzamide  |  G007-LK  |  Dehydrocorydaline chloride  |  AG14361  |  Iniparib  |  AZD-2461  |  BGP-15  |  Fucosterol  |  JW 55  |  EB-47 dihydrochloride  |  UPF 1069  |  AZ6102  |  iRucaparib-AP6  |  ME0328  |  MN-64  |  5,?7,?4'-?Trimethoxyflavone  |  Benzamide  |  GeA-69  |  Paris saponin VII  |  PARP14 inhibitor H10  |  BYK204165  |  NU1025  |  Oroxin A

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。